PULM vs. ENLV, BOLT, CLNN, RNXT, ACST, BIVI, NNVC, NRXP, UBX, and ORGS
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Enlivex Therapeutics (ENLV), Bolt Biotherapeutics (BOLT), Clene (CLNN), RenovoRx (RNXT), Acasti Pharma (ACST), BioVie (BIVI), NanoViricides (NNVC), NRx Pharmaceuticals (NRXP), Unity Biotechnology (UBX), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical preparations" industry.
Pulmatrix (NASDAQ:PULM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Pulmatrix has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.
Pulmatrix has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Enlivex Therapeutics has a net margin of 0.00% compared to Pulmatrix's net margin of -75.73%. Pulmatrix's return on equity of -44.05% beat Enlivex Therapeutics' return on equity.
Pulmatrix presently has a consensus price target of $10.00, suggesting a potential upside of 376.19%. Enlivex Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 341.18%. Given Pulmatrix's higher probable upside, research analysts plainly believe Pulmatrix is more favorable than Enlivex Therapeutics.
In the previous week, Pulmatrix had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Pulmatrix and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.47 beat Pulmatrix's score of 0.15 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 3.6% of Pulmatrix shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pulmatrix received 146 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 78.13% of users gave Enlivex Therapeutics an outperform vote while only 50.91% of users gave Pulmatrix an outperform vote.
Summary
Pulmatrix beats Enlivex Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
